Ginkgo Bioworks Holdings (DNA) Operating Leases (2022 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Operating Leases for 5 consecutive years, with $404.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 5.76% year-over-year to $404.1 million; the trailing twelve-month figure through Jun 2026 stood at $404.1 million (down 5.76% YoY), and the FY2025 full-year result was $417.1 million, down 4.94% from the prior year.
• Operating Leases eased to $404.1 million in Q2 2026 per DNA's latest filing, from $410.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $452.3 million in Q2 2024 and bottomed at $221.8 million in Q4 2023.
• Historically, Operating Leases has averaged $396.2 million across 5 years, with a median of $413.3 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Operating Leases plunged 46.32% in 2023, then surged 97.79% in 2024.
• Over 5 years, Operating Leases stood at $413.3 million in 2022, then sank by 46.32% to $221.8 million in 2023, then surged by 97.79% to $438.8 million in 2024, then retreated by 4.94% to $417.1 million in 2025, then retreated by 3.11% to $404.1 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $404.1 million, $410.7 million, and $417.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.